Generated: December 11, 2017
DrugPatentWatch Database Preview
Details for Patent: 8,420,592
« Back to Dashboard
Which drugs does patent 8,420,592 protect, and when does it expire?
Summary for Patent: 8,420,592
|Title:||Methods of treatment using single doses of oritavancin|
|Abstract:|| Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.|
|Inventor(s):|| Lehoux; Dario (Terrebonne, CA), Parr; Thomas R. (Indianapolis, IN), Moeck; Gregory (St. Laurent, CA), Etienne; Pierre (Montreal, CA) |
|Assignee:|| The Medicines Company (Parsippany, NJ) |
Patent Claim Types:|
see list of patent claims
|Use; Composition; Dosage form; |
Foreign Priority and PCT Information for Patent: 8,420,592
|PCT Filed||August 29, 2009||PCT Application Number:||PCT/US2009/055466|
|PCT Publication Date:||March 04, 2010||PCT Publication Number:||
International Patent Family for Patent: 8,420,592
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.